A 52-Week, International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study with a 52-Week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin in Combination with Metformin compared with Sulphonylurea in Combination with Metformin in Adult Patients with Type 2 Diabetes who have Inadequate Glycaemic Control on Metformin Therapy Alone To examine whether, after 52 weeks of oral administration of double-blind treatment, the absolute change from baseline in HbA1c level with dapagliflozin plus metformin is non-inferior to glipizide (su...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Ensayo en fase II, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de ZD6474 en combinación con docetaxel (Taxotereâ) frente a docetaxel solo como tratamiento de segunda línea del cáncer de mama avanzado (CMA) To assess the efficacy of ZD6474 in combination with docetaxel in the treatment of ABC using the progression event count methodology.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A double-blind, randomised, cross-over, multi-centre study, to evaluate onset of effect in the morning in patients with severe Chronic Obstructive Pulmonary Disease (COPD) treated with budesonide/formoterol (Symbicort®Turbuhaler®) 320/9 μg, compared with salmeterol/fluticasone (Seretide® Diskus®) 50/500 μg, both given as one inhalation twice daily for one week each The primary objective is to evaluate early morning efficacy of Symbicort Turbuhaler 320/9 µg one inhalation twice daily compared to Seretide Diskus 50/500 µg one inhalation twice daily in patients wit...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase III, Multicenter, Randomzed, Double-blind, Placebo-controlled, Parallel-group, Treatment-withdrawal Study to Evaluate the Efficacy and Safety of Esomeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Infants Aged 1 to 11 months, Inclusive The primary objective of this study is to evaluate the efficacy of once daily esomeprazole for reducing the esophageal and supraesophageal signs and symptoms of infantile GERD.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Evaluation of Safety and Efficacy of Dapagliflozin in subjects with Type 2 Diabetes who have Inadequate Glycaemic Control on background combination of Metformin and Sulfonylurea Evaluación de la seguridad y la eficacia de dapagliflozina, en pacientes con diabetes tipo 2 con un control glucémico inadecuado sobre un tratamiento de base combinado de metformina y sulfonilurea The primary objective of this study is to compare the change from baseline in haemoglobin A1c (HbA1c) to week 24 between dapagliflozin 10 mg in combination with metformin and sulfonylurea and placebo ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An Open, Multi-Centre and Long-Term Extension Study to Evaluate the Safety and Tolerability of oral Tesaglitazar therapy 1 mg in patients with Type 2 Diabetes Mellitus. (Protocol Amendment Nr.1, date 2005-04-06) The primary objective is to monitor long-term safety and tolerability of tesaglitazar 1 mg, with or without other oral antidiabetic drugs, when administered up to 104 weeks in an extension study from ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Multi-centre, Double-blind, Double-Dummy, Placebo-controlled, Parallel Group, Randomised, Phase IIb Proof of Concept Study with 3 oral dose groups of AZD3480 or donepezil during 12 weeks treatment in patients with Alzheimer’s Disease Estudio en fase IIB, multicéntrico, doble ciego, controlado con placebo, de grupos paralelos y aleatorizado, de tratamiento con 3 dosis orales de AZD3480 o donepezilo durante 12 semanas en pacientes con enfermedad de Alzheimer. Prueba de concepto To prove the concept that AZD3480 improves cognition in Alzheimer's disease patients in relation to placebo and donepezil, assessed as change from baseline on Alzheimer's Disease Assessment Scale - Co...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study to assess the effect of AZD3241 in Multiple System Atrophy • To assess the safety and tolerability of AZD3241. • To determine the effect of AZD3241 on microglia activation, as measured by [11C]PBR28 binding.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An 18-week, International, Multi-centre, Randomized, Parallel-group, Double-Blind, Active-Controlled Phase IIIb Study to Evaluate the Efficacy and Safety of Saxagliptin in combination with Metformin in Comparison with Sitagliptin in combination with Metformin in Adult Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy alone To compare that, after 18 weeks of oral administration of double-blind treatment, the change from baseline in HbA1c achieved with saxagliptin 5 mg per day added onto metformin is non-inferior to sitag...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

To assess the effects of AZD4901 when given in multiple doses to females with Polycystic Ovary Syndrome To determine change from baseline of LH area under the concentration curve from time zero to 8 hours postdose [AUC(0-8)] at Day 7 in comparison to placebo.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune